CS
CLDX icon

Candriam SCA’s Celldex Therapeutics CLDX Stock Holding History

Candriam SCA’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9M Buy
481,125
+202,237
+73% +$6.53M 0.08% 217
2026
Q1 		$8.85M Buy
+278,888
New +$7.6M 0.05% 299
2024
Q3 		– Sell
-317,509
Closed -$11.8M – 689
2024
Q2 		$11.8M Hold
317,509
– – 0.07% 235
2024
Q1 		$13.3M Hold
317,509
– – 0.09% 221
2023
Q4 		$12.6M Sell
317,509
-5,000
-2% -$147K 0.09% 224
2023
Q3 		$8.88M Sell
322,509
-228,000
-41% -$7.15M 0.06% 239
2023
Q2 		$18.7M Sell
550,509
-45,000
-8% -$1.52M 0.14% 170
2023
Q1 		$19.7M Buy
595,509
+107,000
+22% +$4.62M 0.14% 170
2022
Q4 		$21.8M Buy
488,509
+70,000
+17% +$2.5M 0.15% 159
2022
Q3 		$11.8M Buy
418,509
+127,715
+44% +$3.92M 0.08% 233
2022
Q2 		$7.84M Buy
290,794
+13,313
+5% +$387K 0.06% 263
2022
Q1 		$9.45M Sell
277,481
-109,740
-28% -$3.51M 0.06% 265
2021
Q4 		$15M Buy
387,221
+206,999
+115% +$9.02M 0.1% 209
2021
Q3 		$9.73M Sell
180,222
-219,463
-55% -$10.3M 0.07% 277
2021
Q2 		$13.4M Buy
399,685
+55,546
+16% +$1.52M 0.09% 243
2021
Q1 		$5.79M Hold
344,139
– – 0.05% 348
2020
Q4 		$6.03M Buy
+344,139
New +$6.19M 0.05% 357
2016
Q1 		– Sell
-5,733
Closed -$1.35M – 638
2015
Q4 		$1.35M Sell
5,733
-3,034
-35% -$661K 0.04% 350
2015
Q3 		$1.39M Sell
8,767
-2,233
-20% -$632K 0.03% 390
2015
Q2 		$4.16M Sell
11,000
-667
-6% -$265K 0.09% 268
2015
Q1 		$4.88M Buy
11,667
+2,334
+25% +$835K 0.1% 258
2014
Q4 		$2.56M Buy
+9,333
New +$2.32M 0.05% 326

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Candriam SCA's CLDX Position: Q2 2026 in Review

Candriam SCA increased its Celldex Therapeutics (CLDX) stake by 73% in Q2 2026, buying an estimated $6.53M and bringing the position to 481,125 shares worth $17.9M. The position accounts for 0.08% of the portfolio, ranked #217.

Candriam SCA first reported a position in CLDX in Q4 2014 and has held it in 22 quarters since. The position peaked at $21.8M in Q4 2022. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Candriam SCA held 481,125 shares of Celldex Therapeutics worth $17.9M as of Q2 2026.
  • Candriam SCA bought 202,237 Celldex Therapeutics shares in Q2 2026, an estimated $6.53M.
  • Celldex Therapeutics made up 0.08% of Candriam SCA's portfolio in Q2 2026, its #217 holding.
  • Candriam SCA first reported a position in Celldex Therapeutics in Q4 2014 and has held it in 22 quarters since.
  • Candriam SCA's Celldex Therapeutics position peaked at $21.8M in Q4 2022.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.